Search results
Roche’s VABYSMO has successful Q1 sales despite Regeneron and Bayer’s EYLEA HD launch
Pharmaceutical Technology via Yahoo Finance· 5 days agoLast week, Roche released promising first-quarter (Q1) 2024 sales figures for VABYSMO, a vascular...
Can At-Home Vision Tests Detect Active Neovascular AMD?
MedPage Today· 4 days agoThree at-home vision-monitoring tools failed to detect worsening neovascular age-related macular ...
Should You Consider Regeneron (REGN) Ahead of Q1 Earnings?
Zacks via Yahoo Finance· 5 days agoAn increase in profits from Dupixent and further uptake of Eylea HD are likely to have aided...
Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024 - Ocular...
Benzinga· 5 days agoTherapeutix, Inc. OCUL "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative ...
EYLEA HD shows promise in long-term clinical trials By Investing.com
Investing.com· 6 days agoHD clinical program during a series of presentations at the Association for Research in Vision and...
...Application for EB-105 - A Novel Trispecific Fusion Antibody for Diabetic Macular Edema (DME) -...
WTNH-TV New Haven· 5 days agoEluminex Biosciences (Eluminex), a privately-held biotechnology company focused on the development...
Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
Zacks via Yahoo Finance· 3 days agoIn August 2023, the FDA approved Eylea HD (higher dose of Eylea) for the treatment of patients with ...
Head to Head Survey: Cognition Therapeutics (NASDAQ:CGTX) vs. Opthea (NASDAQ:OPT)
ETF DAILY NEWS· 20 hours agoCognition Therapeutics (NASDAQ:CGTX – Get Free Report) and Opthea (NASDAQ:OPT – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the ...
Behind the Scenes of Regeneron Pharmaceuticals's Latest Options Trends - Regeneron Pharmaceuticals...
Benzinga· 5 days agoThe company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; ...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 6 days agoALPHARETTA, Ga., April 30, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today